ARMC6

Across TCGA pan-cancer cohorts, ARMC6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARMC6 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARMC6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARMC6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where ARMC6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.478	0.826	<.001	75	view →
PDAC	DFS	Quartile	III,IV	0.475	0.979	.006	25	view →
LUAD	DFS	Median	III,IV	0.928	0.553	.011	5	view →
CCRCC	OS	Median	II,III,IV	0.886	0.749	.031	1	view →
LSCC	DFS	Median	III,IV	0.882	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARMC6–HNSC (DFS)

Open the HNSC breakdown →